SanegeneBio and Genentech entered a global licensing agreement aimed at advancing an RNA interference (RNAi) therapeutic program, underscoring continued pharmaceutical interest in genetic medicines ...
Arrowhead Pharmaceuticals recently reported dosing the first subjects in a Phase 1/2a trial of ARO-DIMER-PA, an RNAi drug candidate designed to silence both PCSK9 and APOC3 to address atherosclerotic ...
23h
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million
This biotech firm develops RNAi therapeutics for rare and serious diseases, leveraging clinical partnerships to advance its pipeline.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results